CBLI

Cleveland BioLabs Stock Price

2.00
0.03 (1.52%)
Upgrade to Real-Time
Regular Market
2.00
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Cleveland BioLabs Inc CBLI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 1.52% 2.00 13:59:15
Close Price Low Price High Price Open Price Previous Close
1.95 2.0245 1.95 1.97
Bid Price Ask Price Spread News
1.99 2.01 0.02 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
131 39,938 $ 1.99 $ 79,585 186,006 0.50 - 5.10
Last Trade Time Type Quantity Stock Price Currency
13:59:15 10 $ 2.00 USD

Cleveland BioLabs Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 26.03M 13.02M 6.48M $ 1.11M $ - -0.23 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cleveland BioLabs News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CBLI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.982.10461.85441.9978,0440.021.01%
1 Month1.772.381.622.12188,2420.2312.99%
3 Months2.263.651.622.77445,436-0.26-11.5%
6 Months1.614.691.273.42811,8120.3924.22%
1 Year1.025.100.503.33672,9820.9896.08%
3 Years3.505.100.503.29241,740-1.50-42.86%
5 Years4.395.550.503.60227,053-2.39-54.44%

Cleveland BioLabs Description

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.